

UMKC/UWC Data Analytics Training in Health Sciences Fellowship

Due to some ongoing Visa delays, as well as match of scholars and projects, three out of four of the scholars supported were more senior and had already achieved their PhD. Therefore, the metric of graduation within 18 months was not applicable. However, these scholars were asked to develop new projects that could be fundable from their work at UMKC.

TravelActivities:

data analysis. Dr. Breytenbach produced a proposal for a pilot project which is now an ongoing collaboration between Drs. Breytenbach and Patterson. The abstract from the draft is attached as an appendix to the report.

Dr. Pearce and Dr. Wyckoff worked to determine the potential for performing pharmacogenomic analysis at UMKC, which would extend the reach of work that Dr. Mongi Benjeddou at UWC is currently performing. We were able to replicate the necessary resources for much of the project, but were unable to locate the appropriate radiation source either at UMKC or at UM Columbia for the project. We are still working to find this necessary tool. However, while at UMKC, Dr. Pearce, Mr. Sante, and Ms. Shivani Gargvanshi (a current UMKC Graduate student) worked to determine the feasibility of nanopore sequencing for pharmacogenomics projects both here and at UWC. The proposed platform is cost

utilized to enhance the amount of research, the number of grants applied for and received, and the relationship with UWC will enable potential more applications and a wider field of potential commercialization for such applications.

These opportunities are of course best pursued when there is mutual shared interest in the outcomes and potential grants available. Mutually beneficial projects will emerge which ultimately are funded and sustainable. Incorporation of these projects into the fabric of the Precision Medicine Institute will increase the reach of the institute, enable greater funding (enabling funding from sources such as the NIH D5 program and others) and open access to more international partnerships and global commercialization opportunities.

An excellent opportunity for research funding was the new D5 Africa grant cycle that launched at the NIH and this allowed Dr. Wyckoff to discuss potential projects while at UWC given the deadline of a August 23rd LOI. That deadline was later adjusted.

RFA Link <https://grants.nih.gov/grants/guide/rfafiles/RFARM-22-023.html>

Building on this grant opportunity and the likely commercialization of the W* .82 518.11 Td [(, Cg)][(, Cg)][(, Cg)]

Ongoing Activities:

Centered around drug screening

Bringing in Iman Roomaney, Haly Holmes, and CHS personnel

Multiple grant opportunities implementation science and data analysis

Drs. Fisher, Joubert, Wyckoff

Our discussion noted that this would be an effective way to continue collaborations between the UWC and UMKC Schools of Pharmacy, with an emphasis on shared infrastructure.

Appendix 1: paper abstract from Samson Olesi

Appendix 2: Draft proposabstractfrom Dr. Breytenbach

Appendix 3Flyer